Investor Presentaiton

1H FY24 - Business Performance Overall resilient ex-large PO^ 1H/FY24 Segment Performance [Crore] 1H/FY24 1H/FY23 Y-o-Y FDF 617 498 24% APIs 1,226 1,263 -3% CDMO-Synthesis^ 474 1,297 -63% Bio 89 57 56% Total Revenues 2,406 3,115 -23% CDMO-Synthesis 20% Bio 4% APIs 51% 1H/FY24 Business Mix FDF 25% Formulation (FDF) ■ In-line Q2 recovery in ARV business driving +24% growth in H1 and continue to track healthy underlying demand Developed markets sales increased on higher volume growth and stable pricing. Additional products will be launched in the coming periods APIs Stable; steady ARV API and strong delivery in Oncology (+51%) compensated for decline in Other API (-24%) ■ Demand for CMO opportunities upbeat with on-going advantage from Global supply chain diversification CDMO-Synthesis ■ Declined due to large PO executed last year ■ Base pipeline projects scaling up well; executing on scientific led approach to BD Signed first Ag-chem supply contract in Q1 and manufacturing plant will be ready in 15 to 18 months Commercial Validation of Products at Animal health site will be initiated in H2. R&D site (u/LSPL) will be ready by Mar 2024 Bio Record +56% growth, fueled by CDMO services Bio-catalysis expertise enhanced in select small molecules projects ■ R2 capacities being optimized; optimizing capacity going on-line from Dec'23 ^ FY23 includes material Purchase Order (PO) supplies to Big Pharma; reflected in CDMO-Synthesis segment. Contractual supplies was completed in Dec-22 16 Laurus Q2 & H1 FY 2024 Investor Presentation | October 20, 2023 LAURUS Labs Knowledge. Innovation. Excellence

View entire presentation